Boston-based well being IT firm COTA Inc. nabbed $34 million in progress financing to additional construct its most cancers care knowledge analytics companies.
The sequence D financing spherical was led by Baptist Well being South Florida and ONC Capital with participation from EW Healthcare, Horizon BCBS, Boston Millennia Companions and different current traders.
“The extra capital mixed with our elevated knowledge entry positions COTA for large progress and allows us to drive innovation in oncology utilizing real-world knowledge,” stated Michael Doyle, president and CEO of COTA, in a press release. “Our high-quality knowledge and know-how options will enhance how most cancers is handled and supply a lot wanted readability to sufferers as they navigate their most cancers journey.”
The corporate, launched in 2011, has raised greater than $90 million. Different notable backers embody Celgene, Memorial Sloan Kettering, Novartis and IQVIA.
RELATED: COTA is a Fierce Healthcare Fierce 15 honoree
As a part of the deal, Baptist Well being South Florida secured a seat on COTA’s board of administrators that will probably be crammed by Leonard Kalman, M.D., chief medical officer of Miami Most cancers Institute of Baptist Well being South Florida. COTA is a licensee of each knowledge and mental property developed at Baptist Well being South Florida’s Miami Most cancers Institute.
“COTA has develop into a nationwide chief in most cancers affected person knowledge analytics,” Kalman stated in a press release. “Their highly effective analytics instruments allow suppliers to quickly reply medical questions so as to make higher choices about medical trial participation, and within the realm of inhabitants well being.”
Together with the funding, COTA introduced the growth of its knowledge entry by greater than 300%, which now effectively exceeds 1 million oncology affected person data. Varian, an oncology options firm, made a $20 million funding within the firm with an settlement for the 2 corporations to collaborate to create Clever Most cancers Care instruments for choice help. They’re exploring an providing that mixes COTA’s real-world knowledge with Varian’s patient-reported outcomes, officers stated.
RELATED: Trade Voices—How real-world EHR knowledge are enhancing our understanding of COVID-19
Varian has additionally negotiated an possibility to accumulate the corporate at a later date.
In 2020, COTA is projected to double its life sciences prospects from eight to 16 and prolonged its analysis collaboration settlement with the U.S. Meals and Drug Administration (FDA).
COTA knowledge had been utilized in a number of regulatory filings with the FDA and European Medicines Company as exterior management arms, COTA officers stated, they usually count on the elevated document entry will help new regulatory filings in 2021, officers stated.